Business Combination, Contingent Consideration, Annual Payments

No definition available.

Name:	mnk_BusinessCombinationContingentConsiderationAnnualPayments
Namespace Prefix:	mnk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Business Combination, Contingent Consideration, Potential Payment

+ References

No definition available.

+ Details

Name:	mnk_BusinessCombinationContingentConsiderationPotentialPayment
Namespace Prefix:	mnk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of Nuclear Reactors Relied on For Supply of Raw Material

+ References

No definition available.

+ Details

Name:	mnk_NumberofNuclearReactorsReliedonForSupplyofRawMaterial
Namespace Prefix:	mnk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Nuclear Research Reactors Used To Source Raw Material

+ References

No definition available.

+ Details

Name:	mnk_NumberofNuclearResearchReactorsUsedToSourceRawMaterial
Namespace Prefix:	mnk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Suppliers of Unique Raw Material

+ References

No definition available.

+ Details

Name:	mnk_NumberofSuppliersofUniqueRawMaterial
Namespace Prefix:	mnk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Restricted Cash, Fair Value Disclosure

+ References

No definition available.

+ Details

Name:	mnk_RestrictedCashFairValueDisclosure
Namespace Prefix:	mnk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=25498275&loc=d3e2207-128464

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Surrender Value

-URI http://asc.fasb.org/extlink&oid=6507153

+ Details

Name:	us-gaap_CashSurrenderValueFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueInputsDiscountRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

Financial Instruments and Fair Value Measurements (Narrative) (Details) (USD $)	12 Months Ended					12 Months Ended		12 Months Ended			12 Months Ended									12 Months Ended
	Sep. 26, 2014 supplier reactor	Sep. 26, 2014 Novartis 2015 and 2016	Sep. 26, 2014 Novartis, Subsequent to 2016 till FDA Approval	Sep. 26, 2014 Novartis, Subsequent to FDA Approval	Sep. 26, 2014 BioVectra Financial Results	Sep. 26, 2014 CNS Therapeutics, Inc.	Oct. 01, 2012 CNS Therapeutics, Inc.	Sep. 26, 2014 Questcor Pharmaceuticals, Inc.	Aug. 31, 2014 Questcor Pharmaceuticals, Inc.	Aug. 14, 2014 Questcor Pharmaceuticals, Inc.	Sep. 26, 2014 Questcor Pharmaceuticals, Inc. BioVectra Financial Results	Sep. 26, 2014 2.85% term loan due April 2016	Sep. 26, 2014 4.00% term loan due February 2022	Sep. 26, 2014 Debentures 8.00% debentures due March 2023 Level 2	Sep. 26, 2014 Debentures 9.50% debentures due May 2022 Level 2	Apr. 30, 2013 Senior Notes 3.50% notes due April 2018	Sep. 26, 2014 Senior Notes 3.50% notes due April 2018 Level 1	Apr. 30, 2013 Senior Notes 4.75% notes due April 2023	Sep. 26, 2014 Senior Notes 4.75% notes due April 2023 Level 1	Sep. 26, 2014 Senior Notes 5.75% notes due August 2022	Aug. 31, 2014 Senior Notes 5.75% notes due August 2022	Sep. 26, 2014 Carrying Value Level 1	Sep. 27, 2013 Carrying Value Level 1	Sep. 26, 2014 Carrying Value Level 3	Sep. 27, 2013 Carrying Value Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition					$ 45,000,000		$ 6,900,000			$ 0
Maximum contingent payments for acquisition							9,000,000.0	215,000,000.0
Discount rate						1.00%		4.70%			1.30%	2.85%	4.00%							5.75%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability						7,000,000		195,800,000	195,400,000
Business Combination, Contingent Consideration, Annual Payments		25,000,000	25,000,000
Business Combination, Contingent Consideration, Potential Payment				25,000,000
Restricted cash																						69,800,000	24,000,000
Cash surrender value of life insurance																								$ 69,000,000	$ 67,700,000
Stated interest rate														8.00%	9.50%	3.50%	3.50%	4.75%	4.75%		5.75%
Number of Suppliers of Unique Raw Material	8
Number of Nuclear Research Reactors Used To Source Raw Material	3
Number of Nuclear Reactors Relied on For Supply of Raw Material	2